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 Exploiting information from cellular pathways and molecular 
networks for machine learning analyses of omics data
 Summary & Discussion
May, 2016 2
Luxembourg Centre for Systems Biomedicine (LCSB)
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LCSB – Research Groups & Interdisciplinarity
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Research Focus & Main Goals
“Small N, Large P“
problem
Research focus: Analysis of omics data from case/control studies
 GOALS: Interpret biological differences between patients and controls,
identify candidate disease genes & biomarkers for validation
Patients Controls
~50k-600k
features
(genes,
proteins,
SNPs, etc.)
~100 – 1000 samples
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Overview of machine learning analysis types for omics data
Unsupervised Analyses:
(no sample labels used)
- Clustering samples (columns)
- Clustering biomolecules (rows)
- Bi-Clustering (rows & columns)
Supervised Analyses
(using labelled training data):
- Differential expression analysis
- Pathway enrichment analysis
- Network/causal reasoning canalysis
- Sample classification/regression
- Gene/protein function classification 
“hard“
“hard“
“hard“
“easy“
“easy“
“hard“
“hard“
“hard“
Complexity:
Example: High-
throughput gene 
expression data
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Common challenges for functional genomics data analysis (1)
• Small number of samples in relation to large number of biomolecules
(“Small N, Large P“ problem)  “curse of dimensionality“
• Large number of uninformative and/or functionally redundant biomolecules
(shared function & expression/activation pattern)
• Real signal shifted and scaled by additive and multiplicative noise
bias prior to 
normalization
after 
normalization
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Common challenges for functional genomics data analysis (2)
• Outliers (among biomolecules or samples) and transcriptional amplification in 
sample subset
• Imbalances in no. of samples per condition (e.g. lack of control samples)
• Confounding factors and inadequate matching of patients & controls
False colour heat map (left) and bar chart (right) of distances between microarrays
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The “curse of dimensionality“
For increasing numbers of 
biomolecules/features:
• the space spanned by these
features grows exponentially
 the available data
becomes sparse
 more data points
needed to train
reliable diagnostic
models
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Strategies to address common issues in omics analysis
Statistical approaches:
• Use dimension reduction techniques, dedicated methods to exploit on-chip replicates
and spike-in controls, model averaging methods for machine learning (e.g. ensemble 
classification, consensus clustering)
Data integration methods / exploiting prior biological knowledge:
• Apply meta-analyses across multiple studies, combining information across 
complementary omics & clinical data in supervised machine learning models
• Analyse and integrate data on the level of cellular pathways & molecular networks
Computer-assisted study design / power calculation:
• Design the study with a sufficient number of replicates per class/condition and 
balanced classes; reduce impact of confounding factors via algorithmic sample 
selection/matching
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Using prior knowledge in omics data analysis - Overview
Data integration at the 
level of biomolecules:
• Exploit functional relationships 
between biomolecules:
 cellular pathway membership
 protein complex membership
 interaction in gene regulatory
or protein interaction networks
• Exploit biomolecular relationships
across different omics:
 genes encoding proteins
 enzymes converting metabolites
…
Data integration at the level of samples:
• Exploit meta information for each sample 
(clinical data, sample quality, storage duration)
• Exploit correlation patterns across different 
omics data collected for the same samples
...
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Pathway-based sample classification (PathVar software)
Motivation: Gene/protein expression alterations in diseases tend to be
co-ordinated at the level of cellular pathways
 Use “pathway fingerprints“ (weighted sums of gene expression levels from
all pathway members) as candidate biomarkers with increased robustness
Omics dataCellular pathwaysPathway databases
Compute weighted sum of
expression levels for each
pathway (e.g. using PCA)
Pathway-level activity
measures (fingerprints) 
Map expression
levels
Min. size:
10 genes
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Pathway-level sample classification results 
• Map omics data onto Gene Ontology (GO) biological processes
(example: Parkinson‘s disease case/control post-mortem brain transcriptomics data)
• Use “pathway fingerprints“ and a Support Vector Machine for classification
(10-fold cross-validation; feature selection: empirical Bayes moderated t-statistic)
87.5 ± 17.784.2 ± 18.286.7 ± 18.591.7 ± 13.6GO - MDS
95 ± 10.592.5 ± 12.195 ± 10.589.2 ± 14.2GO - PCA
84.2 ± 18.290 ± 12.984.2 ± 13.981.7 ± 17.5GO - Max.
71.7 ± 24.979.2 ± 23.368.3 ± 25.171.7 ± 21.9GO - Min.
86.7 ± 14.379.2 ± 20.181.7 ± 17.576.7 ± 18.8GO - Stddev.
91.7 ± 13.695 ± 10.591.7 ± 13.684.2 ± 13.9GO - Median
89.2 ± 14.292.5 ± 12.190 ± 12.984.2 ± 13.9GO - Mean
92.5 ± 12.192.5 ± 12.189.2 ± 14.289.2 ± 14.2Gene-level model
100503010Attribute type
Accuracy and stddev. for different numbers of selected attributes
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Molecular networks as prior knowledge (GenePEN software)
Motivation: Disease-associated perturbations are often localized in biological networks. 
Finding these network clusters may help us to develop more robust biomarker models.
Question: How can we find clustered gene/protein groups efficiently, accounting for 
their predictivity and connectedness in the network?
Example sub-network (Meta-
analysis of 8 post-mortem 
microarray datasets for 
substantia nigra tissue) :
Over-expressed in PD
Under-expressed in PD
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GenePEN - Workflow
Input:
• Omics dataset X (p rows = biomolecules, n columns = samples)
• Class labels y (e.g. “patient” or “control”)
• Table A of interactions/similarities between rows in X (e.g. protein-protein interactions)
Output:
• A subset of discriminative biomolecules (rows in X) representing a connected component 
in A  ( an altered sub-network) that provides a signature to classify new samples
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GenePEN - Approach
Idea: Cast the feature selection as an optimization problem, maximizing two quantities:
 the estimated diagnostic prediction accuracy of the classifier
 the connectedness of selected features/biomolecules in the network
 formulate an objective function (details not shown):
loss-function (minimize error)       trade-off parameter penalty-function (network grouping)
 Output after optimization procedure: A selection of features (w) that minimizes the objective 
function (features which minimize the prediction error and are well-grouped in the network)
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• Parkinson’s disease test dataset: Microarray gene expression data from post mortem
brain samples (substantia nigra) of 43 PD patients and 50 controls (Zhang et al., 2005)
• Network data: Human genome-scale protein-protein interaction network constructed from 
80,543 public, direct physical interactions between 10,042 proteins. 
• Comparison to other approaches: GenePEN was compared against related methods 
with other penalty functions:
 Lasso (Tibshirani, 1996)               sparse feature selection, but no feature grouping
 Elastic Net (Zou & Hastie, 2005)  cannot account for external network data
 Pairwise Elastic Net  can take external network data into account
(Lorbert, 2010 & 2013)                     to achieve a partial grouping of features
GenePEN – Application to Parkinson‘s disease data
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Comparison: Largest clusters found for 50 selected genes
Lasso Elastic Net PEN (2010)
PEN (2013) GenePEN  cluster of 34 genes
(accuracy comparable to best alternative)
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GenePEN: Biological analysis of predictive sub-networks
Largest connected graph component 
identified for Parkinson’s disease:
• red = over-expressed in PD
blue = under-expressed in PD
node borders = individual statistical 
significance (from gray to blue with 
increasing significance)
• individually significant genes are  
significantly over-represented in the 
sub-network (p = 0.01)
• GSK3B contains polymorphisms
associated with Parkinson’s disease
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Summary
• Many tools are available to address statistical challenges in omics data analysis 
 computer-guided study design, dedicated normalization methods, 
exploiting prior knowledge from molecular networks and pathways
• PathVar uses “pathway activity fingerprints“ derived from omics data and known
pathway definitions to build robust diagnostic machine learning models
• GenePEN discovers discriminative sub-networks for diagnostic sample 
classification and enables an interpretation of disease-associated molecular 
alterations at the network level
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